A Phase IIA, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 a Liposomal Grb2 Antisense Oligonucleotide in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia AML Who Are Ineligible for Intensive Induction Therapy

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT02781883

Study #:
STUDY00004217

Start Date:
Oct 03, 2016

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT02781883

View Complete Trial Details & Eligibility at ClinicalTrials.gov